BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32964398)

  • 21. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer.
    Moody TW; Ramos-Alvarez I; Jensen RT
    Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor.
    Takasaki I; Watanabe A; Yokai M; Watanabe Y; Hayakawa D; Nagashima R; Fukuchi M; Okada T; Toyooka N; Miyata A; Gouda H; Kurihara T
    J Pharmacol Exp Ther; 2018 Apr; 365(1):1-8. PubMed ID: 29363578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary adenylate cyclase activating polypeptide-mediated intracrine signaling in the testicular germ cells.
    Li M; Funahashi H; Mbikay M; Shioda S; Arimura A
    Endocrine; 2004 Feb; 23(1):59-75. PubMed ID: 15034198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary adenylyl cyclase-activating polypeptide (PACAP) and its receptor (PAC1-R) are positioned to modulate afferent signaling in the cochlea.
    Drescher MJ; Drescher DG; Khan KM; Hatfield JS; Ramakrishnan NA; Abu-Hamdan MD; Lemonnier LA
    Neuroscience; 2006 Sep; 142(1):139-64. PubMed ID: 16876955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH-induced PACAP and PAC1 receptor expression in pituitary gonadotrophs: a possible role in the regulation of gonadotropin subunit gene expression.
    Purwana IN; Kanasaki H; Oride A; Mijiddorj T; Shintani N; Hashimoto H; Baba A; Miyazaki K
    Peptides; 2010 Sep; 31(9):1748-55. PubMed ID: 20553777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
    Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
    Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures.
    Cohen JR; Resnick DZ; Niewiadomski P; Dong H; Liau LM; Waschek JA
    BMC Cancer; 2010 Dec; 10():676. PubMed ID: 21143927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PACAP-PAC1 Signaling Regulates Serotonin 2A Receptor Internalization.
    Hayata-Takano A; Shintani Y; Moriguchi K; Encho N; Kitagawa K; Nakazawa T; Hashimoto H
    Front Endocrinol (Lausanne); 2021; 12():732456. PubMed ID: 34759890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma.
    Bardosi S; Bardosi A; Nagy Z; Reglodi D
    J Mol Neurosci; 2016 Oct; 60(2):171-8. PubMed ID: 27566169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus.
    Costa L; Santangelo F; Li Volsi G; Ciranna L
    Hippocampus; 2009 Jan; 19(1):99-109. PubMed ID: 18727050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PACAP-Induced PAC1 Receptor Internalization and Recruitment of Endosomal Signaling Regulate Cardiac Neuron Excitability.
    Parsons RL; May V
    J Mol Neurosci; 2019 Jul; 68(3):340-347. PubMed ID: 30054797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.